News: Ann Richmond

Target Acquired for Aggressive Tumor

Friday, September 28th, 2012

Angiosarcoma, a rare, aggressive tumor that arises from cells that line blood vessels, has a mortality rate of around 80 percent. Because of their constant contact with the blood stream, these tumors can spread quickly and freely throughout the body. The INK4a/ARF locus on chromosome 9 – a region that encodes tumor suppressor proteins – […]

New Drug Mutes More Melanomas

Thursday, April 26th, 2012

Therapies targeted to a specific mutation in the BRAF gene can significantly reduce tumor burden in metastatic melanoma. But these therapies are not suitable for melanomas lacking the mutation, and even tumors carrying the BRAF mutation eventually become resistant to those therapies. Using human melanoma tumors implanted into mice, Ann Richmond, Ph.D., and colleagues assessed […]

Detour Around the Estrogen Receptor

Tuesday, January 25th, 2011

About 75 percent of early-stage breast cancers are fueled by estrogen. These estrogen receptor (ER)-positive tumors typically respond to anti-estrogen therapies like tamoxifen, but about a quarter of patients develop resistance to these therapies and the tumors recur. A multi-institutional team of researchers has now identified a potential new target for treating these tumors. The […]